Why do people get lvads

Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.

Last updated: April 8, 2026

Quick Answer: People get Left Ventricular Assist Devices (LVADs) primarily as a bridge to heart transplantation or as destination therapy for end-stage heart failure when transplantation isn't possible. Approximately 250,000 Americans have advanced heart failure, with LVADs implanted in about 2,500 patients annually in the U.S. The first successful LVAD implantation occurred in 1966 by Dr. Michael DeBakey, and the FDA approved the first LVAD for destination therapy in 2003. These devices can extend survival by 2-3 years compared to medical therapy alone for ineligible transplant patients.

Key Facts

LVADs are implanted in approximately 2,500 patients annually in the United States
The first successful LVAD implantation was performed in 1966 by Dr. Michael DeBakey
FDA approved the first LVAD for destination therapy in 2003 (HeartMate XVE)
LVADs can extend survival by 2-3 years compared to medical therapy alone for transplant-ineligible patients
Approximately 250,000 Americans have advanced heart failure that might benefit from LVAD therapy

Overview

Left Ventricular Assist Devices (LVADs) are mechanical pumps surgically implanted to support heart function in patients with severe heart failure. The development of LVADs began in the 1960s, with the first successful implantation occurring in 1966 by pioneering cardiac surgeon Dr. Michael DeBakey at Baylor College of Medicine. Initially conceived as temporary support for patients awaiting heart transplantation, LVAD technology has evolved significantly over decades. The landmark REMATCH trial (2001) demonstrated that LVADs could provide long-term survival benefits for patients ineligible for transplantation, leading to FDA approval of the first destination therapy device in 2003. Today, LVADs represent a critical advancement in managing end-stage heart failure, with approximately 250,000 Americans having advanced heart failure that might benefit from this therapy. Modern devices like the HeartMate 3 (approved in 2017) have improved durability and reduced complications compared to earlier models.

How It Works

An LVAD is a mechanical circulatory support device that takes over the pumping function of the left ventricle, the heart's main pumping chamber. The system consists of three main components: a pump implanted in the chest, a driveline that exits through the abdominal wall, and external components including a controller and power sources. The pump draws oxygen-rich blood from the left ventricle through an inflow cannula and propels it into the aorta via an outflow cannula, bypassing the weakened ventricle. Most modern LVADs use continuous-flow technology with a rotary pump mechanism that creates blood flow without pulsatility. The device is powered through a percutaneous driveline connected to external batteries and a controller that monitors device function. Patients typically carry two batteries providing 10-14 hours of power each, with a backup system for safety. The surgical implantation requires cardiopulmonary bypass and takes 4-6 hours, with patients typically hospitalized for 2-4 weeks postoperatively for recovery and training on device management.

Why It Matters

LVADs matter profoundly because they address the critical shortage of donor hearts for transplantation while providing life-extending therapy for end-stage heart failure patients. With only about 3,500 heart transplants performed annually in the U.S. but over 250,000 patients with advanced heart failure, LVADs bridge this therapeutic gap. For destination therapy patients ineligible for transplantation, LVADs improve survival by 2-3 years compared to medical therapy alone and significantly enhance quality of life by relieving heart failure symptoms. The technology has evolved to reduce major complications like pump thrombosis and stroke, with the latest devices showing 2-year survival rates exceeding 80%. Beyond individual patient benefits, LVADs reduce healthcare costs associated with repeated heart failure hospitalizations and represent a major advancement in mechanical circulatory support that continues to evolve toward fully implantable systems.